Can be galectin-3 a novel marker in determining mortality in hemodialysis patients?(Retracted article. See vol.49,pg.942,2016)


OZKAN G., ULUSOY Ş., MENTEŞE A., GÜVERCİN B., KARAHAN S. C. , YAVUZ A., ...More

CLINICAL BIOCHEMISTRY, vol.48, no.12, pp.768-773, 2015 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 48 Issue: 12
  • Publication Date: 2015
  • Doi Number: 10.1016/j.clinbiochem.2015.05.003
  • Journal Name: CLINICAL BIOCHEMISTRY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.768-773
  • Karadeniz Technical University Affiliated: Yes

Abstract

Background: Cardiovascular (CV) mortality is common in hemodialysis (HD) patients. There are some difficulties involved in determining CV risk. Galectin-3 is a molecule with a demonstrated correlation with CV mortality and which is approved in the stratification of heart failure (HF) risk. The purpose of this study was to assess the previously uninvestigated relationship between galectin-3 and cardiac mortality in HD patients.